Please assess the completion status of the following clinical trial:

Trial Title: HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Able and willing to give written informed consent~2. Age ≥55 years~3. a. In Stage 1: Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, and a diagnosis of AMD in the contralateral eye; b. In Stage 2: Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, that is non-foveal, as determined by the central reading centre, or has a CFI rare variant genotype and meets inclusion criteria 3a, and a diagnosis of AMD in the contralateral eye (except if monocular)~4. GA lesion(s) within an acceptable size on FAF, in the study eye~5. The GA lesion in the study eye must reside completely within the FAF image~6. Up to 25% of the enrolled study population are permitted to have CNV in the fellow eye~7. Have a BCVA of ≥24 letters (6/95 or 20/320 Snellen acuity equivalent), using ETDRS charts, in the study eye~8. a. In Stage 1: Meet one of the pre-specified AMD genetic subgroup criteria; b. In Stage 2: Genotyping is not required for study eligibility~9. Able to attend all study visits and complete the study procedures~10. Women of child-bearing potential must have a negative pregnancy test within 2 weeks prior to randomisation (not required for postmenopausal women) or provide documentation of being surgically sterilised~Exclusion Criteria:~1. a. In Stage 1: Carriers of excluded genetic variants; b. In Stage 2: Subjects are excluded if they have a clinical diagnosis of Stargardt Disease or other retinal dystrophies~2. Have a history, or evidence, of CNV in the study eye~3. Presence of moderate/severe or worse non-proliferative, diabetic retinopathy in the study eye~4. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the study eye~5. History of intraocular surgery in the study eye within 12 weeks prior to Visit 1~6. Have clinically significant cataract that may require surgery during the study period in the study eye~7. Presence of moderate to severe glaucomatous optic neuropathy, uncontrolled intraocular pressure (IOP), despite use of two or more topical agents; or a history of glaucoma-filtering or valve surgery~8. Axial myopia of greater than -8 diopters in the study eye~9. Have received any investigational product for the treatment of GA within the past 6 months or 5 half-lives (whichever is longer), other than nutritional supplements such as the age-related eye disease study (AREDS) formula~10. Have received a gene or cell therapy at any time.~11. Have a contraindication to the protocol specified corticosteroid regimen~12. Are unwilling to use two forms of contraception (one of which being a barrier method) for 90 days post-dosing, if relevant~13. Active malignancy within the past 12 months, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with a stable prostate-specific antigen (PSA) ≥ 12 months~14. Have any other significant ocular or non-ocular medical or psychiatric condition which, in the opinion of the Investigator, may either put the subject at risk or may influence the results of the study

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GT005 Medium Dose (Type: EXPERIMENTAL): Approximately 83 subjects are planned, with subjects randomised to GT005 Medium Dose.
- GT005 High Dose (Type: EXPERIMENTAL): Approximately 83 subjects are planned, with subjects randomised to GT005 High Dose.
- Untreated control (Type: NO_INTERVENTION): Approximately 83 subjects are planned, with subjects randomised to untreated control.

Based on this trial design, predict the completion outcome and termination type (if applicable).